312637-48-2 Usage
Description
THIQ, also known as (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide, is a potent and selective melanocortin 4 receptor agonist. It plays a crucial role in the regulation of energy homeostasis, eating behavior, and sexual functions.
Uses
Used in Pharmaceutical Industry:
THIQ is used as a therapeutic agent for regulating energy homeostasis, eating behavior, and sexual functions. It acts as a potent and selective melanocortin 4 receptor agonist, modulating the activity of parasympathetic preganglionic neurons in the brainstem and regulating sympathetic and parasympathetic preganglionic neurons.
Biological Activity
Potent and selective melanocortin 4 (MC 4 ) receptor agonist (IC 50 values are 1.2, 761 and 2067 nM for human MC 4 , MC 3 and MC 1 receptors respectively). Enhances intracavernosal pressure and stimulates erectile activity in rats ex copula following systemic administration.
Check Digit Verification of cas no
The CAS Registry Mumber 312637-48-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,2,6,3 and 7 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 312637-48:
(8*3)+(7*1)+(6*2)+(5*6)+(4*3)+(3*7)+(2*4)+(1*8)=122
122 % 10 = 2
So 312637-48-2 is a valid CAS Registry Number.
312637-48-2Relevant articles and documents
PHARMACOLOGICAL CHAPERONES FOR TREATING OBESITY
-
Page/Page column 2/18, (2008/06/13)
The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.